Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) traded today at $49.14, breaking its 52-week high. So far today approximately 889,000 shares have been exchanged, as compared to an average 30-day volume of 596,000 shares.
Jazz Pharmaceuticals (NASDAQ:JAZZ) has potential upside of 5.7% based on a current price of $48.27 and analysts' consensus price target of $51.00. The stock should discover initial support at its 50-day moving average (MA) of $38.06 and subsequent support at its 200-day MA of $36.16.
Jazz Pharmaceuticals, Inc. develops and markets treatments for neurological and psychiatric conditions. The Company produces treatments for cataplexy, excessive daytime sleepiness, and ethylene glycol and methanol poisoning in humans.
Over the past year, Jazz Pharmaceuticals has traded in a range of $17.48 to $49.14 and is now at $48.27, 176% above that low. The 200-day and 50-day moving averages have moved 0.64% higher and 1.09% higher over the past week, respectively.
